Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.9 (1.91%)
Data as of 05/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
05/23/17Pacira Pharmaceuticals Announces Resignation of James Scibetta
PARSIPPANY, N.J., May 23, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James Scibetta is resigning as the company’s president to become chief executive officer of an undisclosed private early-stage oncology company. Pacira will allocate Mr. Scibetta’s operational oversight responsibilities to the current leadership team and does not intend to name a successor. Mr. Scibetta will remain with the company through June 30 to ensure a seamless transition p... 
Printer Friendly Version
05/10/17Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
PARSIPPANY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at A replay of the webcast will be archived on ... 
Printer Friendly Version
05/04/17Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results
-- EXPAREL® Net Product Sales Up 6% Year-Over-Year -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2017 (GLOBE NEWSWIRE) --  Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2017. “We’re pleased with our strong first quarter highlighted by important strategic advances a... 
Printer Friendly Version
05/03/17New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option
Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction     PARSIPPANY, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- According to a new national survey of over 1,500 oral surgery patients or their parents, more than seven in 10 respondents indicated they would opt for a non-opioid medication to treat postsurgical pain from third molar (wisdom tooth) extraction if given the choice. Approximately 80 percent... 
Printer Friendly Version

Corporate Presentation

Corporate Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Susan Mesco
(973) 451-4030